Evaluating Choice of Biologics for Isolated Small-Bowel Crohn’s Disease
Lay Summary In this study we evaluated the effectiveness of vedolizumab (anti-integrin) vs ustekinumab/risankizumab (anti-interleukin) therapy for isolated small-bowel Crohn’s disease using a real-world, multicenter national database. We found that anti-interleukin therapy was more effective for inducing steroid-free remission and reducing hospitalizations.
Authors
- June Tome (ORCID: https://orcid.org/0000-0001-9914-1695)
- Darrell S. Pardi (ORCID: https://orcid.org/0000-0003-0420-8784)
- Francis A. Farraye (ORCID: https://orcid.org/0000-0001-6371-2441)
- Saqr Alsakarneh (ORCID: https://orcid.org/0000-0002-8776-2176)
- Jana G. Hashash (ORCID: https://orcid.org/0000-0001-8305-9742)
Institutions
- Jacksonville College (US)
- WinnMed (US)
- Mayo Clinic in Arizona (US)
- Mayo Clinic in Florida (US)
- University of Missouri–Kansas City (US)
Publication Details
- Journal
- Inflammatory Bowel Diseases
- Published
- 2025-11-06
- DOI
- https://doi.org/10.1093/ibd/izaf294
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00